Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.

Agustín Ciapponi Ariel Esteban Bardach Carla Colaci Federico Rodriguez Cairoli Fernando J Argento Ernesto Korbenfeld Sebastian Garcia Marti

Published in: Revista peruana de medicina experimental y salud publica (2024)

NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performance in PFS and overall response rate and a trend towards worse overall survival than T-DXd.

Keyphrases

positive breast cancer
squamous cell carcinoma
small cell lung cancer
epidermal growth factor receptor
locally advanced
physical activity
metastatic breast cancer
free survival
type diabetes
glycemic control
radiation therapy
metabolic syndrome
adipose tissue